Tirzepatide for Weight Loss: The Dual GIP/GLP-1 Medication Explained
What is tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is sometimes casually described online as a “GLP-2” weight-loss medication, but that wording is not scientifically accurate: tirzepatide does not target the GLP-2 receptor. It acts on GIP and GLP-1 pathways. Zepbound is the tirzepatide brand approved for chronic weight management in eligible patients, while Mounjaro is approved for type 2 diabetes.
How is it different from semaglutide?
Semaglutide acts primarily through the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. Both are prescription medications that require individualized medical evaluation. The right option depends on health history, treatment goals, contraindications, tolerance and other clinical factors rather than simply choosing the newest medication.
Medical weight-loss support in South Florida
SoFlo Medical Center offers medically supervised weight-management consultations in Pembroke Pines and Miami Gardens. A provider can review your history and explain available options, realistic expectations, nutrition support and follow-up. Treatment plans are personalized rather than one-size-fits-all.
Important safety information
Tirzepatide may cause side effects and is not appropriate for every patient. A licensed provider should review your medical history and medications before treatment. Seek medical care for severe or concerning symptoms.
Comments